Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
11/2003
11/20/2003WO2003094853A2 Compositions and methods for combating lower urinary tract dysfunctions with delta opioid receptor agonists
11/20/2003WO2003094840A2 Induction of antigen specific immunologic tolerance
11/20/2003WO2003094836A2 Methods and products for enhancing immune responses using imidazoquinoline compounds
11/20/2003WO2003094812A1 Abuse-resistant opioid solid dosage form
11/20/2003WO2003070192A9 Compositions and methods for surrogate antibody modulation of an immune response and transport
11/20/2003WO2003061696A3 Systems and methods for photodynamic therapy
11/20/2003WO2003055915A3 Human netrin receptor and uses thereof
11/20/2003WO2003054012A3 Leptin proteins
11/20/2003WO2003050504A3 Methods and compositions to treat cardiovascular disease usin g 1419, 58765 and 2201
11/20/2003WO2003045993A3 Protein biopolymer markers predictive of type ii diabetes
11/20/2003WO2003044172A3 Composition comprising and method of using angiopoietin-like protein 3 angptl3
11/20/2003WO2003042357A3 Enzymes
11/20/2003WO2003032984A8 2-phenyl benzimidazoles and imidazo-[4,5]-pyridines as cdsi/chk2-inhibitors and adjuvants to chemotherapy or radiation therapy in the treatment of cancer
11/20/2003WO2003032866A3 Detection and treatment of intravascular lesions
11/20/2003WO2003029210A3 Heteroaryl substituted tetrazole modulators of metabotropic glutamate receptor-5
11/20/2003WO2003024403A3 Carbohydrate supplementation and rehydration composition
11/20/2003WO2003024357A3 Microfabricated nanopore device for sustained release of therapeutic agent
11/20/2003WO2003017946A3 Non-oxidatively metabolized compounds and compositions, synthetic pathways therefor, and uses thereof
11/20/2003WO2003016506A3 Secreted proteins
11/20/2003WO2003014105A9 Bicyclic compound, production and use as hiv inhibitors
11/20/2003WO2003009873A3 Use of pulmonary surfactant as humectant
11/20/2003WO2003006447A3 Interaction inhibitors of tcf-4 with beta-catenin
11/20/2003WO2003004613A3 Novel pgc-1 isoforms and uses therefor
11/20/2003WO2003000864A3 Nucleic acid-associated proteins
11/20/2003WO2002102315A3 QUINAZOLINE AND PYRIDO[2,3-d]PYRIMIDINE INHIBITORS OF PHOSPHODIESTERASE (PDE) 7
11/20/2003WO2002101045A3 Vanilloid receptor-related nucleic acids and polypeptides
11/20/2003WO2002090530A3 Kinases and phosphatases
11/20/2003WO2002087583B1 Use of hiv-protease inhibitors to block cell migration and/or invasion, tissue infiltration and oedema formation
11/20/2003WO2002072146A3 Combination of nateglinide or repaglinide with at least one further antidiabetic compound
11/20/2003WO2002069906A3 Compounds and methods for the treatment of urogenital disorders
11/20/2003WO2002067941A3 Combination comprising a signal transduction inhibitor and an epothilone derivative
11/20/2003WO2002062362A3 Antiviral and antibacterial composition
11/20/2003WO2002058731A3 Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions
11/20/2003WO2002056823A8 Redox therapy for tumors
11/20/2003WO2002055547A3 Sfrp and peptide motifs that interact with sfrp and methods of their use
11/20/2003WO2002053092A8 Methods employing and compositions containing plaque associated molecules for prevention and treatment of atherosclerosis
11/20/2003WO2002044417A9 Expression analysis of inhibitor of differentiation nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
11/20/2003WO2002044159A8 1-(2-m-methanesulfonamidophenylethyl)-4-(m-trifluoromethylphenyl)piperazine and pharmaceutically acceptable salts and solvates thereof and their use in the treatment of incontinence
11/20/2003WO2002041910A3 Methods and compositions for the treatment of diseases of the eye
11/20/2003WO2002038744A3 Proteases
11/20/2003WO2002033050A8 Methods and compositions for promoting the maturation of monocytes
11/20/2003WO2002032407A3 Use of hyaluronic acid derivatives for the prevention of inflammatory arthritis
11/20/2003WO2002002055A3 Antifungal compounds and methods of use
11/20/2003WO2001085664A8 Compounds and methods for regulating bacterial growth and pathogenesis
11/20/2003US20030217379 Defective tyrosine phosphatase animal model for diagnosing and treating diabetes and eating disorders
11/20/2003US20030216778 Composite staple for completing an anastomosis
11/20/2003US20030216699 Drug delivery; restenosis therapy
11/20/2003US20030216574 Pyrazine based inhibitors of glycogen synthase kinase 3
11/20/2003US20030216568 Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation,compositions and use as medicaments
11/20/2003US20030216558 Novel compositions and methods for cancer
11/20/2003US20030216549 Comprises modified chemokine for use as antiinflammatory, viricidal or antiallergenic agent
11/20/2003US20030216479 Novel compositions comprising 2,2-Bis (4-hydroxy-3-methylphenyl) heptane and uses thereof
11/20/2003US20030216461 Mixture of cyclooxygenase inhibitor, non-steroid antiinflammatory drug and acetaminophen; concurrent administering
11/20/2003US20030216458 Combination therapy for the treatment of migraine
11/20/2003US20030216446 Aryl ureas as kinase inhibitors
11/20/2003US20030216443 Antidiabetic agents; using mixture of enzyme inhibitors
11/20/2003US20030216425 Tricyclic compounds as mrp1-inhibitors
11/20/2003US20030216424 Pyrroloquinoline quinone drugs for treatment of cardiac injury and methods of use thereof
11/20/2003US20030216422 Methods for treating multidrug resistance
11/20/2003US20030216420 Pharmaceutical composition for treating fecal incontinence and anal itch
11/20/2003US20030216413 Catecholamine pharmaceutical compositions and methods
11/20/2003US20030216410 Administering to a cancer patient an indole-2-one derivative containing pyrrole ring as protein kinase inhibitor together with a cyclooxygenase inhibitor to treat the cancer
11/20/2003US20030216401 Anti-obesity 1, 2, 3, 4, 10, 10a-hexahydropyrazino[1, 2-a] indoles
11/20/2003US20030216399 A dipeptide containing bi or tri-heterocylic ring with nitrogen atom which forms amide with carbonyl group of dipeptide chain; useful for treating osteoporosis, congestive heart failure and accelerates wound healing
11/20/2003US20030216391 Oxazole or thiazole-ethyl-oxy-indane acetic acid derivatives; useful for the treatment of diseases such as diabetes, obesity, hyperlipidemia and atherosclerosis
11/20/2003US20030216369 Administering compounds which inhibit heat shock protein 90 proteins; methods block Rb negative or deficient cells in the G2/M phase of the cell cycle and rapidly causes their destruction
11/20/2003US20030216359 Administering vitamin D or a derivative and a cytotoxic agent or a glucocorticoid and, optionally, a bisphosphonate
11/20/2003US20030216352 Multicomponent complex for use with a substrate
11/20/2003US20030216349 Method for treating arrhythmias
11/20/2003US20030216348 Aminosugar, glycosaminoglycan, and S-Adenosylmethionine composition for the treatment and repair of connective tissue
11/20/2003US20030216329 Composition, formulations & kit for treatment of respiratory & lung disease with dehydroepiandrosterone(s) steroid & an anti-muscarinic agent(s)
11/20/2003US20030216325 Novel peptides as NS3-serine protease inhibitors of hepatitis C virus
11/20/2003US20030216314 Methods of reducing angiogenesis
11/20/2003US20030216312 Administering a bactericidal/permeability-increasing (BPI) protein product
11/20/2003US20030216307 Pharmaceutical formulation composed of a polymer blend and an active compound for time-controlled release
11/20/2003US20030216297 Pharmaceutical composition
11/20/2003US20030216294 Synergistic effect of a sulfonylurea and/or non-sulfonylurea Kchannel blocker, and a phosphodiesterase 3 type inhibitor
11/20/2003US20030216290 Methods and compositions of treating and/or preventing diabetic retinopathy with pericyte apoptosis inhibitors
11/20/2003US20030216288 Methods and compositions for treating aids and HIV-related disorders using 1414, 1481, 1553, 34021, 1720, 1683, 1552, 1682, 1675, 12825, 9952, 5816, 10002, 1611, 1371, 14324, 126, 270, 312, 167, 326, 18926, 6747, 1793, 1784, or 2045 molecules
11/20/2003US20030216287 N-(2-chlorophenyl) hydroxy- or alkoxyalkanamides, e.g.,N-(5-Chloro-2-hydroxyphenyl)-2-(2-hydroxyphenoxy)acetamid e); can deliver a broad range of active agents by various routes.
11/20/2003US20030215921 Vascular endothelial growth factor-2
11/20/2003US20030215898 Methods for using 22045, a human cyclic nucleotide phosphodiesterase
11/20/2003US20030215889 Membrane preparation comprising calcium channel transport protein for screening and identifying modulator of ion transport; for prevention and treatment of nervous tissue injuries and diabetes
11/20/2003US20030215879 Comprise enzymatic polypeptide for use in the treatment of inflammation; aniinflammatory agents
11/20/2003US20030215852 Novel pancortin-Pablo protein interactions and methods of use thereof
11/20/2003US20030215840 Identifying compounds capable of treating atherosclerosis, reperfusion injury, hypertension, restenosis, arterial inflammation, heart failure, thrombosis and endothelial cell disorders
11/20/2003US20030215823 Uses of galanin GALR2 receptors
11/20/2003US20030215822 Comprises nucleotide sequences coding polypeptide for use in diagnosis, treatment and prevention of cell proliferative, autoimmune/inflammatory, cardiovascular, neurological and developmental disorder
11/20/2003US20030215531 Compositions and methods of use for extracts of Rutaceae plants
11/20/2003US20030215528 Prophylaxis and prevention of cancer, tumors, hyperplasia, hypertrophy or dysplasia comprising administering nitrates such as nitroglycerin; angiogenesis inhibitors
11/20/2003US20030215527 Novel substituted benzimidazole dosage forms and method of using same
11/20/2003US20030215520 Generation of ozone and oxygen from air, then flowing the gas mixture into water using a venturi; water treatment
11/20/2003US20030215493 Composition and method for dermatological treatment
11/20/2003US20030215489 Chemosensitizing with liposomes containing oligonucleotides
11/20/2003US20030215462 Use of UGT inhibitors to increase bioavailability
11/20/2003US20030215457 Comprising a nucleic acid, a polypeptide encoded by the nucleic acid, and a compound, preferably an antibody or fragment thereof, that binds to the polypeptide, preferably binding to the extracellular domain of LIV-1 polypeptide
11/20/2003US20030215452 Methods and compositions for treating hematological disorders using 131, 148, 199, 12303, 13906, 15513, 17822, 302, 5677, 194, 14393, 28059, 7366, 12212, 1981, 261, 12416, 270, 1410, 137, 1871, 13051, 1847, 1849, 15402, 340, 10217, 837, 1761, 8990 or 13249 molecules
11/20/2003US20030215451 In treatment (including prevention) or identification of a human subject at risk of tissue damage, preferably liver or heart tissue damage
11/20/2003US20030215448 Compositions and methods for treating hyperimmune response in the eye
11/20/2003US20030215446 CATT-tetranucleotide repeat polymorphism at position-817 of the human Mif gene that functionally affects the activity of the Macrophage Inhibitory Factor (MIF) promoter in gene reporter assays
1 ... 643 644 645 646 647 648 649 650 651 652 653 654 655 656 657 658 659 660 661 662 663 ... 1151